Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)
Study sponsor: UroGen Pharma Ltd. · URGN
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-02-02Actual
Enrollment · participants8Actual
Source updated2024-09-19Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.